ARIScience is RESHAPING THE FUTURE OF DRUG DISCOVERY
Identifying new cures for societal diseases through AI and Quantum Chemistry
Our proprietary novel in-silico platform unites AI, quantum chemistry, computer vision and bio-chemistry to design and discover molecule compounds that interrupt disease pathways.
Assessed via established in vitro and in vivo assays, these small molecule compounds interrupt proteins allosterically, directly or formatively.
We are purusing treatments for prevalent neurodegenerative, inflammatory and infections diseases by focusing on the interruption of aberrant, overexpressed or pathogenic proteins.
We are thrilled to announce that we've been awarded an advanced protein impact via small molecule research contract by the United States Biomedical Advanced Research and Development Agency in April of 2023.
Interrupt Proteins Like Never Before
Our novel in silico quasi quantum calculation methodology combined with a unique computation-first approach and diverse, purpose-driven team of experts delivers unparalleled results. Merging traditionally disparate scientific disciplines and utilizing cutting-edge technology and methodologies allows us to efficiently iterate and refine drug candidates, leading to higher success rates and a faster time-to-societal-impact for our clients. Our leading approach and expertise have resulted in a proven track record of success, and we are dedicated to bringing advanced science driven therapeutics to patients.